Home Newsfeeds Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.

Evercore ISI Group Maintains Outperform on Microsoft, Lowers Price Target to $280

By Benzinga Newsdesk

January 19, 10:00 AM

Evercore ISI Group analyst Kirk Materne maintains Microsoft (NASDAQ:MSFT) with a Outperform and lowers the price target from $300 to $280.

MSFT

Reported Late Tuesday March 28, Equinox Gold Announces Up To $200M In Gold Prepay And Gold Purchase And Sale Arrangements

By Happy Mohamed

March 29, 12:41 AM

All dollar amounts shown in United States dollars, unless otherwise indicated. This is a "designated news release" for the purposes of the Company's prospectus supplement dated November 21, 2022, to its

EQX

RBC Capital Maintains Sector Perform on New Relic, Raises Price Target to $75

By Benzinga Newsdesk

February 8, 10:39 AM

RBC Capital analyst Rishi Jaluria maintains New Relic (NYSE:NEWR) with a Sector Perform and raises the price target from $55 to $75.

NEWR

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia

By Vandana Singh

December 28, 8:31 AM

Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.

ALZN

Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform

Related Posts

Evercore ISI Group Maintains Outperform on Microsoft, Lowers Price Target to $280

Reported Late Tuesday March 28, Equinox Gold Announces Up To $200M In Gold Prepay And Gold Purchase And Sale Arrangements

RBC Capital Maintains Sector Perform on New Relic, Raises Price Target to $75

EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia